A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
SCRI Development Innovations, LLC
Dana-Farber Cancer Institute
H. Lee Moffitt Cancer Center and Research Institute
Amgen
University of Iowa
Eli Lilly and Company
Novartis
H. Lee Moffitt Cancer Center and Research Institute
Dana-Farber Cancer Institute
Mateon Therapeutics
Novartis
Columbia University
Vanderbilt-Ingram Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Novartis
Cylene Pharmaceuticals
CASI Pharmaceuticals, Inc.
Callisto Pharmaceuticals